{"id":"NCT05718466","sponsor":"Henry Ford Health System","briefTitle":"Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy","officialTitle":"Prospective Study of Stereotactic Radiosurgery Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-line Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2016-12","completion":"2016-12","firstPosted":"2023-02-08","resultsPosted":"2023-07-17","lastUpdate":"2023-07-17"},"enrollment":35,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent or Progressive Glioblastoma"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":[]},{"type":"DRUG","name":"Chemotherapy","otherNames":["Either irinotecan or temozolomide or carboplatin or etoposide"]},{"type":"RADIATION","name":"Fractionated radiosurgery","otherNames":[]}],"arms":[{"label":"Fractionated Radiosurgery and Bevacizumab","type":"EXPERIMENTAL"},{"label":"Bev with Chemo","type":"ACTIVE_COMPARATOR"}],"summary":"This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.","primaryOutcome":{"measure":"Local Tumor Control","timeFrame":"2 months","effectByArm":[{"arm":"Fractionated Radiosurgery and Bevacizumab","deltaMin":14,"sd":null},{"arm":"Bev With Chemo","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":18},"commonTop":[]}}